PODD - NASDAQ
Insulet Corporation
$145.31
+1.4%Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
At a Glance
Live Snapshotpodd
Research Development Expenses
Last Annual Value
301.10M
3-Year CAGR
19%
5-Year CAGR
15%
10-Year CAGR
21%
Insulet Corporation Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Insulet Corporation NASDAQ:PODD | 301.10M | 13.7% | 13.5% | 18.4% | |
 Zimmer Biomet Holdings, Inc. NYSE:ZBH | 458.50M | -0.0% | 1.0% | 2.3% | |
 STERIS plc NYSE:STE | 112.90M | 4.7% | 11.2% | 7.1% | |
 Biogen Inc. NASDAQ:BIIB | 1.95B | -10.2% | -10.5% | -0.1% | |
74.30M | 2.8% | 7.1% | 7.3% | ||
 Labcorp Holdings Inc. NYSE:LH | 0.00 | N/A | N/A | N/A | |
 Quest Diagnostics Incorporated NYSE:DGX | 0.00 | N/A | N/A | N/A | |
 Waters Corporation NYSE:WAT | 195.18M | 3.7% | 3.0% | 4.5% | |
 DexCom, Inc. NASDAQ:DXCM | 594.90M | 5.6% | -0.3% | 14.3% |
Insulet Corporation Fair Value Envelope
Related Guides
Continue your PODD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.